QRX-042

N/A

Report date: 2025/01/26 19:29:33
NME

Base Information

Drug NameQRX-042
Drug Alias Nameantisense RNA targeting W1282X mutation (ProQR Therapeutics)QRX-042
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionCystic fibrosis transmembrane conductance regulator modulators
TargetsCystic fibrosis transmembrane conductance regulator
Therapy Area/IndicationsCystic Fibrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlands
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesProqr Therapeutics Nv
China Registration ClassN/A

Develop Information

Active CompaniesProqr Therapeutics Nv
Inactive CompaniesN/A
Active IndicationsCystic Fibrosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A